DrugPatentWatch Database Preview
FLONASE SENSIMIST ALLERGY RELIEF Drug Profile
Which patents cover Flonase Sensimist Allergy Relief, and when can generic versions of Flonase Sensimist Allergy Relief launch?
Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There are eight patents protecting this drug.
This drug has two hundred and eighty-four patent family members in forty-one countries.
The generic ingredient in FLONASE SENSIMIST ALLERGY RELIEF is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for FLONASE SENSIMIST ALLERGY RELIEF
| International Patents: | 284 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 17 |
| Patent Applications: | 538 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FLONASE SENSIMIST ALLERGY RELIEF |
| DailyMed Link: | FLONASE SENSIMIST ALLERGY RELIEF at DailyMed |
Recent Litigation for FLONASE SENSIMIST ALLERGY RELIEF
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| GlaxoSmithKline Intellectual Property Management Limited v. Sandoz Inc. |
Synonyms for FLONASE SENSIMIST ALLERGY RELIEF
| (6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate |
| (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate |
| 397864-44-7 |
| 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| 779352-12-4 |
| 911210-90-7 |
| Alisade |
| Allermist |
| Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)- |
| Arnuity Ellipta |
| Avamys |
| Avamys pound>> Veramyst pound>> Allermist |
| BCP18136 |
| BDBM50354851 |
| CHEBI:74899 |
| CHEMBL1676 |
| D06315 |
| DB08906 |
| DTXSID60228586 |
| Flonase Sensimist |
| Fluticasone fuorate |
| Fluticasone furancarboxylate |
| Fluticasone furoate |
| Fluticasone furoate (JAN/USAN/INN) |
| Fluticasone furoate [USAN:INN] |
| fluticasonum furoas |
| FT-0668768 |
| Furamist |
| furoate de fluticasone |
| furoato de fluticasona |
| GSK 685 698 |
| GSK 685698 |
| GW 685698 |
| GW 685698X |
| GW-685698 |
| GW-685698X |
| GW6 |
| gw685698 |
| GW685698X |
| JS86977WNV |
| SCHEMBL140504 |
| UNII-JS86977WNV |
| Veramyst |
| Veramyst (TN) |
| ZINC3992105 |
US Patents and Regulatory Information for FLONASE SENSIMIST ALLERGY RELIEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Glaxosmithkline Cons | FLONASE SENSIMIST ALLERGY RELIEF | fluticasone furoate | SPRAY, METERED;NASAL | 022051-002 | Aug 2, 2016 | OTC | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FLONASE SENSIMIST ALLERGY RELIEF
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2007510448 | Start Trial |
| Slovenia | 1305329 | Start Trial |
| Brazil | PI0610671 | Start Trial |
| New Zealand | 549683 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for FLONASE SENSIMIST ALLERGY RELIEF
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1305329 | 08C0014 | France | Start Trial | PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111 |
| 2506844 | 2018C/022 | Belgium | Start Trial | PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
| 1305329 | 300343 | Netherlands | Start Trial | 300343, 20210803, EXPIRES: 20230110 |
| 1305329 | C 2008 007 | Romania | Start Trial | PRODUCT NAME: FUROATDE FLUTICAZONA SI SOLVATIIACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/07/434/001; DATE OF NATIONAL AUTHORISATION: 20080111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/434/001, EU/1/07/434/002, EU/1/07/434/003; DATE OF FIRST AUTHORISATION IN EEA: 20080111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
